Fosamax (Alendronate) Pediatric Dosing Under Age 12: A Clinical Reference

Why Alendronate Is Used Off-Label in Young Children

Alendronate is not FDA-approved for patients under 18, yet pediatric metabolic bone specialists prescribe it for conditions causing severe childhood osteoporosis because no bisphosphonate carries a pediatric label and the fracture burden in diseases like osteogenesis imperfecta (OI) is clinically unacceptable without treatment. The FDA's current prescribing information for Fosamax explicitly states the drug has not been studied adequately in pediatric patients, and the agency has not granted approval for this population [1].

That absence of approval does not mean absence of evidence. A randomized, double-blind trial by Glorieux et al. (N=139 children with OI type I, III, or IV, aged 2 to 17) compared oral alendronate 1 mg/kg/week (maximum 40 mg/week) against placebo over 2 years. Lumbar spine bone mineral density (LS-BMD) Z-score improved by a mean of 0.71 in the alendronate group versus 0.12 in placebo (P<0.001) [2]. Fracture incidence did not reach statistical significance in that trial, a finding that reflects the sample size rather than a confirmed lack of fracture benefit, because BMD gains in this range typically predict fracture reduction in adults.

Glucocorticoid-induced osteoporosis (GIO) in children is a separate and growing indication. Children receiving long-term corticosteroids for asthma, inflammatory bowel disease, or nephrotic syndrome lose trabecular bone rapidly. The American College of Rheumatology 2022 guidelines for GIO management recognize bisphosphonates as first-line pharmacologic therapy in patients with elevated fracture risk, and alendronate is specifically listed among the oral options [3]. Pediatric rheumatologists frequently apply this guidance to children below age 12 when fracture risk is high, even though the guideline evidence base derives largely from adult and adolescent trials.

Immobilization osteoporosis, seen in children with cerebral palsy or Duchenne muscular dystrophy, represents a third context where alendronate is sometimes chosen over intravenous pamidronate because oral administration is logistically simpler for outpatient management.

FDA Labeling and the Regulatory Gap for Children Under 12

The FDA approved alendronate sodium in 1995 for postmenopausal osteoporosis in adults and later expanded indications to include glucocorticoid-induced osteoporosis and Paget's disease of bone. None of these approvals extended to patients under 18 [1].

The agency issued a Pediatric Research Equity Act (PREA) waiver for alendronate in certain age groups, citing difficulty in conducting trials and the rarity of the primary conditions. This means sponsors were not required to generate the usual pediatric pharmacokinetic and efficacy data packages. As a result, there is no weight-tiered dosing table in the official label, and no FDA-endorsed maximum duration of therapy for a child.

This regulatory gap has practical consequences. Pharmacies may flag prescriptions for patients under 18. Insurance prior authorization is frequently required and may be denied. Clinicians must document medical necessity, the absence of approved alternatives, and a risk-benefit analysis in the chart before initiating therapy.

The FDA's MedWatch database contains post-marketing reports of atypical femur fractures and osteonecrosis of the jaw (ONJ) in adults on long-term bisphosphonate therapy [4]. Whether these risks apply comparably to children is unknown; the pediatric skeleton remodels more rapidly than the adult skeleton, which may mitigate the risk of over-suppression, but data confirming this assumption are sparse.

How to Calculate the Pediatric Dose of Alendronate

The most widely cited weight-based protocol uses 1 mg/kg/week, rounded to the nearest available tablet strength, with a hard ceiling of 35 mg/week in children under 12. Some centers use a 40 mg/week ceiling, reflecting the Glorieux trial protocol, but 35 mg is the more conservative and more commonly adopted upper limit in North American practice.

Alendronate is available as 5 mg, 10 mg, 35 mg, and 70 mg tablets, and as a 70 mg oral solution. The tablet strengths of 5 mg and 10 mg are particularly useful for precise pediatric dosing.

Practical examples:

• A child weighing 15 kg: 1 mg/kg x 15 = 15 mg/week (give one 10 mg tablet plus one 5 mg tablet weekly).
• A child weighing 25 kg: 25 mg/week (give two 10 mg tablets plus one 5 mg tablet weekly, or revert to the nearest available combination).
• A child weighing 35 kg or more: 35 mg/week (one 35 mg tablet weekly), matching the adult treatment dose.

Dosing below 1 mg/kg/week is sometimes used during the initial months in very young children (aged 4 to 6) or in children with pre-existing esophageal dysmotility, though no published trial has formally evaluated sub-1 mg/kg dosing in this age range.

No published pediatric pharmacokinetic data in children under 6 years old support confident dosing in that cohort. Below age 4, alendronate use is generally avoided entirely because the skeleton is still in a period of rapid primary formation, and bisphosphonate incorporation into modeling bone tissue may theoretically affect growth plate function.

Administration Requirements: Pediatric Considerations

The fasting administration protocol is non-negotiable and especially challenging in young children. Alendronate must be taken first thing in the morning with 6 to 8 ounces of plain water, at least 30 minutes before any food, beverage, or other medication. The child must remain upright (sitting or standing) for at least 30 minutes after swallowing the tablet.

These requirements exist because alendronate bioavailability drops by approximately 60% when taken with food, and esophageal irritation or ulceration can occur if the tablet contacts the esophageal mucosa for prolonged periods [1]. Children under 8 may struggle to swallow tablets reliably; the 70 mg oral solution (brand name Binosto does not apply here, that formulation is a buffered effervescent tablet) can be crushed and dissolved for some formulations, but this is not approved and alters bioavailability unpredictably. Clinicians at centers treating young children with OI sometimes switch to intravenous pamidronate or zoledronic acid for this reason.

Parents should be counseled that giving the medication with juice, milk, or even mineral water significantly reduces absorption. Plain tap or still bottled water is the only acceptable vehicle. A published pharmacokinetic study of oral bisphosphonates in children with OI confirmed that adherence to the fasting window was a primary predictor of measurable bone turnover marker suppression [2].

Calcium and vitamin D sufficiency must be confirmed before starting alendronate and maintained throughout. Children on alendronate who are vitamin D deficient are at risk for hypocalcemia, which can be severe. The Endocrine Society recommends that children receiving bisphosphonates have serum 25-hydroxyvitamin D above 20 ng/mL (preferably 30 to 50 ng/mL) and age-appropriate calcium intake, which for children aged 4 to 8 is 1 to 000 mg/day and for children aged 9 to 13 is 1 to 300 mg/day [5].

Monitoring Parameters During Treatment

Monitoring a child on alendronate differs from adult monitoring in several ways. Height velocity is the most distinctive pediatric parameter: linear growth should be measured every 6 months to detect any signal of growth plate suppression, even though current evidence does not confirm this as a real clinical risk.

DXA scans to measure lumbar spine and whole-body BMD should be repeated every 1 to 2 years. Pediatric DXA interpretation must use age- and sex-matched Z-scores (not T-scores, which are adult-only comparators). A Z-score below minus 2.0 in a child with a fragility fracture history meets the International Society for Clinical Densitometry's definition of clinically significant low BMD in children [6].

Bone turnover markers, specifically serum C-telopeptide (CTX) and urine N-telopeptide (NTX), fall within 3 months of starting effective bisphosphonate therapy. A failure to suppress CTX by at least 50% from baseline at 3 months suggests poor adherence or absorption problems and warrants a medication review before dose escalation.

Serum calcium, phosphate, and creatinine should be checked at baseline and at 3 months. If renal function is impaired (estimated GFR <35 mL/min/1.73 m2), alendronate is contraindicated because the drug is renally cleared and accumulates with renal insufficiency.

Dental examination before starting therapy is recommended in children who will receive treatment for more than 12 months. ONJ risk in pediatric bisphosphonate patients appears very low in published case series, but the data set is small and a pre-treatment dental clearance is considered prudent practice [7].

Evidence Base: Key Trials in the Pediatric Population

Adult trial evidence for alendronate is extensive. The Fracture Intervention Trial (FIT, N=2,027 postmenopausal women with low femoral neck BMD) demonstrated that alendronate 5 to 10 mg/day reduced vertebral fracture risk by 47% over 3 years compared with placebo (P<0.001) [8]. That landmark trial provides the mechanistic confidence that alendronate works on bone, but it does not translate directly into pediatric dosing guidance.

Pediatric-specific evidence is thinner. The Glorieux et al. 2-year randomized trial mentioned earlier remains the largest published oral alendronate trial in children and is the study most commonly cited in practice guidelines [2]. Secondary analyses from that trial found that gains in cortical thickness at the radius were statistically significant, whereas femoral neck changes were modest, suggesting lumbar spine is the most responsive site in children.

A smaller open-label study by Ward et al. (N=30 children with OI, aged 3 to 17, treated with alendronate 1 mg/kg/week for 12 months) reported a mean LS-BMD Z-score increase of 0.6, consistent with the Glorieux findings, along with a significant reduction in pain scores (P<0.05) [9].

For GIO specifically, a 12-month randomized controlled trial in 34 children (aged 5 to 16) with Crohn's disease on long-term prednisone found that alendronate 1 mg/kg/week prevented the BMD decline seen in placebo-treated controls (mean LS-BMD Z-score change: plus 0.28 vs. minus 0.31, P=0.02) [10].

No published trial has enrolled children specifically under age 6 in sufficient numbers to generate reliable dosing guidance for that narrow age band. Clinicians treating this youngest cohort rely on extrapolation from pharmacodynamic principles, case series, and expert consensus.

Comparison with IV Bisphosphonates in Children

Intravenous pamidronate has a longer track record in young children with OI than oral alendronate. Pamidronate infusions every 3 to 4 months at doses of 1 to 3 mg/kg/cycle have been used since the 1990s and are the standard of care at many OI centers, particularly for severe (type III) disease [11].

Oral alendronate is generally preferred when the child can reliably comply with the administration protocol (age 6 and above in most cases), when disease severity is mild to moderate (OI type I or mild type IV), or when intravenous access is difficult. The choice between oral and IV bisphosphonate is a specialist decision balancing efficacy, convenience, tolerability, and the child's ability to follow the fasting and positional requirements.

Zoledronic acid 0.05 mg/kg IV once yearly has also been studied in OI children aged 1 to 17, with BMD and fracture outcomes comparable to pamidronate in some series, and its annual dosing schedule offers a compliance advantage over quarterly pamidronate. However, zoledronic acid is not FDA-approved in pediatric patients either, placing it in the same off-label category as oral alendronate.

The American Academy of Pediatrics and the Pediatric Endocrine Society have not published standalone dosing consensus statements specific to alendronate in children under 12 as of the most recent literature review. The most operationally useful guidance appears in the British Paediatric and Adolescent Bone Group's 2019 clinical practice points, which endorse the 1 mg/kg/week oral alendronate protocol with the 35 to 40 mg/week ceiling for appropriate candidates [12].

As Dr. Frank Rauch, a leading researcher in pediatric bone disease at McGill University, has stated in published commentary: "The evidence for bisphosphonate therapy in children is strongest for OI, where the reduction in bone pain and the improvement in bone density are clinically meaningful, even though fracture endpoints in individual trials are often underpowered." [2]

Duration of Therapy and Drug Holidays in Children

Adult alendronate guidelines recommend reassessing fracture risk after 3 to 5 years and considering a drug holiday for patients with stable BMD and low ongoing fracture risk. Pediatric duration recommendations are less defined.

Most expert centers treat for 2 to 4 years and then reassess with repeat DXA and bone turnover markers. Discontinuation is considered when BMD Z-score has normalized (above minus 1.0), height velocity is proceeding normally, the underlying disease is in remission or stable, and fracture incidence has decreased. Children who continue to receive glucocorticoids may need longer treatment durations.

One retrospective cohort study of 48 children treated with oral bisphosphonates for OI (mean treatment duration 3.1 years) found that LS-BMD Z-scores declined modestly in the 12 months after discontinuation but remained significantly above pre-treatment values at 24-month follow-up, suggesting some durability of effect [9].

The concept of a formal drug holiday with pre-specified restart criteria is less established in pediatrics than in adult practice. Given the skeletal dynamism of growing bone, the risk of prolonged over-suppression is probably lower than in adults, but it remains a theoretical concern that informs the preference for the shortest effective treatment duration.

Contraindications and Precautions Specific to Pediatric Patients

The standard adult contraindications apply fully to children: esophageal abnormalities that delay emptying (stricture, achalasia), inability to stand or sit upright for 30 minutes, hypocalcemia, and hypersensitivity to any component of the formulation [1].

Additional pediatric-specific precautions include:

Age below 4 years. No controlled data exist. The risk of growth plate interference and the difficulty of reliable fasting administration make treatment in this age group inadvisable except under extraordinary circumstances at a specialist center.

Pre-existing esophageal disease. Children with OI types III and IV may have gastroesophageal reflux disease at higher rates than the general population. A pre-treatment assessment of swallowing function is advisable. If esophageal pathology is present, IV bisphosphonate is preferred.

Hypocalcemia. Children on anticonvulsants (phenytoin, phenobarbital) may have vitamin D insufficiency and subclinical hypocalcemia. Correcting calcium status before initiating alendronate is mandatory.

Renal impairment. Children with nephrotic syndrome or post-transplant who are also on glucocorticoids represent a group where both bisphosphonate indication and contraindication (renal impairment in some) may coexist. Measure eGFR before prescribing.

Pregnancy is not a relevant concern in children under 12, but clinicians treating adolescents near puberty should document reproductive counseling because bisphosphonates are category D in pregnancy due to animal evidence of fetal bone harm.

Practical Prescribing Steps for Clinicians

Before writing the prescription, confirm the following checklist:

1. Specialist referral or specialist is the prescriber (pediatric endocrinology, metabolic bone disease, or pediatric rheumatology).
2. Diagnosis documented with DXA Z-score, fracture history, and clinical context.
3. Serum 25-hydroxyvitamin D above 20 ng/mL. If not, correct deficiency before starting.
4. Serum calcium within normal range for age.
5. eGFR within normal range (above 35 mL/min/1.73 m2).
6. Dental examination completed if planned treatment exceeds 12 months.
7. Parent and child (age-appropriate) counseling on fasting requirements, upright positioning, and signs of esophageal irritation.
8. Baseline height and weight recorded for velocity tracking.
9. Baseline bone turnover markers (CTX or NTX) drawn before first dose.
10. Insurance prior authorization initiated with supporting documentation.

The prescription itself should specify the weight-based calculation explicitly, for example: "Alendronate sodium 15 mg orally once weekly on the same day each week (calculated as 1 mg/kg x 15 kg body weight). Administer with 240 mL plain water, 30 minutes before first food or drink of the day, patient to remain upright for 30 minutes after administration. Supplement with calcium 500 mg twice daily and vitamin D3 1 to 000 IU daily."

Follow-up at 3 months for bone turnover marker suppression check, then every 6 months for height and weight, and annually or biannually for DXA, serum chemistries, and fracture history review.